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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a malignancy derived from nasopharyngeal epithelial cells. 
One of the molecular NPC markers is cluster of Epidermal Growth Factor Receptor (EGFR) who have 
responsible against the proliferation, differentiation, apoptosis, metastasis and drug resistance. 
Objective: Tumor development was triggered by the excess population of the Epidermal Growth Factor Receptor 
(EGFR). EGFR expression associated with tumors size, positively nodules and advanced tumor stage in NPC 
patients.  
Methods: Using Cross-sectional as study design. Formalin-fixed paraffin-embedded biopsy specimens were 
obtained. The expression of EGFR was studied with immunohistochemistry using EGFR polyclonal antibody 
(Bioss, USA). Assessment of the staining was performed by pathologist consultant used histoscore. The 
Pearson’s correlation test was used to determine the correlation between expression of EGFR and primary tumor 
volume of nasopharyngeal carcinoma. Statistical significance was defined as p <0.05. 
Result: Total samples are 19 patients. The result of EGFR expression in NPC patients with a primary tumor 
volume of 1-50 ml is 5 samples with a weak positive expression and 4 samples with moderate positive 
expression. NPC with a primary tumor volume of 51-100 ml is 2 samples of negative expression, 1 sample of 
weak positive expression, 3 samples with moderate positive expression and 2 samples with strong positive 
expression. NPC with primary tumor volume >100 ml is 1 sample weak positive expression and 1 sample strong 
positive expression. Statistical analysis using Pearson’s exact test was obtained p=0.047 with a correlation 
coefficient 0.461. EGFR expression from all of the patients there was 2 samples (10.53%) negatives, 7 samples 
(36.84%) weak positive, moderate positive was 7 samples (36.84%), and strong positive 3 samples (15.79%).  
Conclusion: There was an association between the expression of EGFR with the primary tumor volume of 
nasopharyngeal carcinoma. 
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Nasopharyngeal carcinoma (NPC) is a malignancy derived from 
lymphoepithelial and epithelial tissues of nasopharynx. 
Nasopharyngeal carcinoma is the most common head and neck 
malignancy with locoregional metastasis [1-3]. The assessment of 
therapy response is using staging, but in fact patients with the same 
stage of NPC could have different responses [4]. this proved that staging 
is not accurate to predict the therapy response for NPC. Epidermal 
Growth Factor Receptor (EGFR) is supposedly associated with NPC 
primary tumor volume, and acts as a marker to predict the therapy 
response and for giving targeted therapy.   
Chua, et al. (2008) proved that the expression and EGFR level 
increased significantly in late stage of NPCs compared to those in early 
stages. The statement also supported by the study conducted in RSUP 
Dr. M. Djamil Padang that revealed EGFR expression increased in stage 
III and IV of NPC [5]. The EGFR examination and measurement of 
primary tumor volume expected to be the better predictors of therapy 
response of NPC. Until now the correlation between EGFR expression 
and primary tumor volume of NPC patients at Out Patient Department 
(OPD) of Otolaryngology Department, Dr. Soetomo General Hospital 
Surabaya has not been clearly known.  
Primary tumor volume of NPC with high level EGFR expression 
known to have the better therapy response using targeted therapy [5], 
but not every NPC with high level EGFR gives complete response, but 
the other studies found that EGFR inhibition didn’t bring significant 
result in restrict NPC proliferation. This might explained there is 
another pathway involved in NPC progresivity [5].  
EGFR is a tyrosin kinase receptor that usually expressed in tumor 
epithelial. This receptor increased using biomolecular and 
immunohistochemistry examinations [6]. The increasing of EGFR 
expression also related with the increasing of NPC staging such as 
tumor volume, lymph node involvement, and distant metastasis that 
affect the prognosis [5]. Many studies found that the increasing of 
EGFR expression related with poor prognosis of NPC [7-10]. High 
EGFR expression in NPC had been reported in 80% NPC biopsies in 
Europe and around 85% NPC patients in China. EGFR expression 
detected in the late stage of NPC. In another study, 234 samples with 
squamous cell carcinomas about 31% EGFR positive and increased 
EGFR expression found in NPC patients [7-10]. Chua et al., found 89% 
positive EGFR expression using immunohistochemistry examination 
from NPC biopsies, meanwhile 11% with negative EGFR expression. 
Chua et al., concluded that there was no difference between EGFR 
expression and NPC staging, tumor size, lymph node enlargement, 
distant metastasis, age and gender [7]. 
The role of EGFR in the development of the NPC in many ways, 
such as improving the cell differentiation, inhibit local immune 
response, stimulate proliferation, induction angiogenesis, and inhibit 
apoptosis [5]. EGFR increase in some carcinomas, it’s a transmembrane 
glycoprotein produced by e-erb-B2 proto oncogene and affected by 
EBV. Active EGFR will trigger three main signaling pathways Ras-Map 
kinase, Janus Kinase (JaK)/Signal Transducer and Activator of 
Transcription (STAT), Phospatidyl Inositol 3-Kinase (PI3K) that relate 
with EGFR activation, increasing of proliferation, cell motility and 
inhibit apoptosis. It also relate with carcinogenesis process that cause 
independent invasive growth epithelial layer of nasopharynx [11-14]. 







Recent studies try to explain the activation mechanisms and EGFR 
function, for the purpose of find a malignancy therapy. But in many 
studies stated that EGFR inhibition did not bring significant result in  
inhibit NPC proliferation. this shows that there is another pathway that 
engages in NPC progresivity [5, 6]. 
Many contradictive results from previous studies led us to do a 
research to find the correlation between EGFR expression and primary 
tumor volume Nasopharyngeal Carcinoma at OPD of Otolaryngology 
Department, Dr. Soetomo General Hospital Surabaya.  
2. MATERIAL AND METHODS 
This is a cross sectional study conducted in May 2017 until May 2018  
for patients whom diagnosed with NPC and did first time check up at OPD 
of Otolaryngology Department, Dr. Soetomo General Hospital Surabaya. 
The inclusion criterias are paraffin block of malignancy biopsies 
enough for EGFR immunohistochemistry examination and also NPC 
patients with nasopharyngeal focused head and neck CT scan at Dr. 
Soetomo General Hospital Surabaya. The exclusion criterias are NPC 
patients with broken paraffin block biopsies or did not fulfill the 
requirements during the process immunohistochemistry examination or 
patients that have already recieved definitive therapy such as 
radiotherapy, chemotherapy or combination, and also were not willing 
to follow the research. 
EGFR expression examined with paraffin block thickness 3-5 μm, 
when there was foung necrotic are then the paraffin block couln ’t be 
use. Endogenous peroxidation activity inhibit with 3% hydrogen 
peroxidation in methanol for 10 minutes with room temperature. This 
slice incubated in 10% lamb plasma in phosphatebuffered saline 
(PBS) for 30 minutes, then continued incubation in 4 oC using rabbit 
polyclonal antibody anti EGFR  bs-0165R for 1 night. After that every 
slice given biotinylated antirabbit immunoglobulin for 10 minutes 
then incubated with streptavidin peroxidase complex for 45 minutes. 
Peroxidation activity visualized using 3.3-diaminobenzidine and also 
stain using hematoxylline. 
EGFR expression is the precipitate intensity that smeared start 
from tawny until dark brown color at membran cell, cytoplasm, or 
both thru immunohistochemistry stained. EGFR expression evaluated 
into 3 semi visual quantitative scales. The outward evaluation/EGFR 
distribution evaluation using outward apprearanced by means of 
stained cells in 500-1000 cells or in 5-10 visual fields with 400x 
enlargement. The intensity evaluation of EGFR done with ascertained 
with the changes brownish red color. Immunohistochemistry stained 
using rabbit polyclonal antibody anti EGFR bs-0165R (Bioss, USA). 
The results based on distribution were: 0=no positive cell found, 
1=positive cell ≤10%, 2=positive cell 11-50%, 3=positive cell 51-
80%, 4=positive cell ≥80%. The results based on instensity were: 
0=no color, 1=weak intensity color (light brown/ pale), 
2=intermediate intensity color (brown), 3=strong intensity (dark 
brown). Histochemistry score is the multiplication between 
distribution and intensity with ratio scale. Final scores were:  
0=negative, 1-2=weak positive (+), 3-6=intermediate positive (++), 
7-12=strong positive (+++). Evaluation scale: ordinal category, score 
0-12. Evaluation done by anatomical pathology specialists.  
NPC Primary tumor volume is the size of primary tumor that 
measured using head and neck CT scan focus on nasopharynx. Primary 
tumor volume measured using 3D volume measurement merk Philips 
Extended Brilliance Workspace. The contrast enhanced areas were 
colored and then combined to get the tumor volume. Tumor volume 
expressed in milli liter [15]. Scales with ratio measurement were done 
by radiology doctors. 
Statistical analysis using descriptive analysis to calculate the 
distribution of EGFR expressions and primary tumor volume based on 
CT-scan findings using data ratio and Pearson’s test with level of 
convidence (α)=0,05. This study already got permission and approval 
by ethical committee Medical faculty of Universitas Airlangga-RSUD. 
Dr. Soetomo Surabaya. 
3. RESULT 
The result of the study is provided as below: 
Table 1. NPC Patients Distribution 
Data Number % 
Age   
31-40 4 21.05 
41-50 10 52.64 
51-60 3 15.79 
61-70 1 5.26 
71-80 1 5.26 
Gender   
Male 15 78.95 
Female 4 21.05 
Ethnic   
Javanese 15 78.95 
Maduranese 4 21.05 
Occupation   
Entrepreneur  8 42.11 
Housewife 1 5.26 
Farmer 9 47.37 
Domestic Employee 1 5.26 
Stage   
I 0 0 
II 1 5.26 
III 3 15.79 
IV 15 78.95 
Primary Tumor Volume   







Histopatology   
WHO I 1 5.26 
WHO II 3 15.79 
WHO III 15 78.95 
Total 19 100.00 
The most age distribution of NPC patients is age range 41-50 years 
old 10 petients (52.64%) patients, followed by age range 31-40 years old                         
4 patients (21.05%), age range 51-60 years old 3 patients (15.79%), age 
range 61-70 years old 1 patient (5.26%), and age range 71-80 years old                    
1 patient (5.26%). The youngest was 32 years old and the eldest was 73 
years old. The most gender of NPC patients is male 15 patients (78.95%), 
meanwhile female 4 patients (21.05%). The comparison between male 
and female was 3.75:1. The most ethnic distribution of NPC patients is 
javanese 15 patients (78.95%) followed by Maduranese 4 patients 
(21.05%). The most occupational distribution of NPC is farmers 9 patients 
(47.37%) followed by enterpreneur 8 patients (42.11%), housewife 1 
patient (5.26%) and domestic employee 1 patient (5.26%). The most 
staging distribution is stage IV 15 patients (78.95%), followed by stage 
III 3 patients (15.79%), stage II 1 patient (5.26%), stage I no patient. The 
most primary tumor volume NPC is 1-50ml 9 patients (47.37%), followed 
by 51-100ml 8 petients (42.11%), >100ml 2 patients (10.52%). The most 
histological type is WHO type III 15 patients (78.95%), followed by WHO 
type II 3 petients (15.79%), and WHO type I 1 patient (5.26%). 
The correlation between EGFR expression and primary tumor volume 
NPC EGFR expression compares with primary tumor volume NPC: 




volume NPC (ml) 
Number 
1-50 51-100 >100  
Negative (-) 0 2 0 2 
Weak Positive (+) 5 1 1 7 
Intermediate Positive (++) 4 3 0 7 
Strong Positive (+++) 0 2 1 3 
Total 9 8 2 19 
p=0.047 
r=0.461 
   
Table 2 above shows the results of EGFR expression examinations on 
NPC with primary tumor volume 1-50 ml were weak positive in 5 patients 
and intermediate positive in 4 patients. NPC with primary tumor volume 
51-100 ml were negative in 2 patients, weak positive in 1 patient, 
intermediate positive in 3 patients, and strong positive in 2 patients. NPC 
with primary tumor volume >100ml were weak positive in 1 patient and 
strong positive in 1 patients.   
Statistical analysis the correlation between EGFR expression and primary 
tumor volume NPC measured using data ratio with normal distribution and 
Pearson’s correlation test (p=0.047) with (r)=0.461. This shows intermediate 
EGFR expression found in primary tumor volume were related with coefisien. 















Picture 1. EGFR stain in NPC tissue shows no brownish red color 
appearance at membrane cell  
 
Picture 2. EGFR stain in NPC tissue shows weak intensity of 
brownish red color appearance at membrane cell  
Picture 3. EGFR stain in NPC tissue shows intermediate intensity of 
brownish red color appearance at membrane cell  
Picture 4. EGFR stain in NPC tissue shows strong intensity of 
brownish red color appearance at membrane cell  
4. DISCUSSION  
This study result showed the EGFR expression in NPC with primary 
tumor volume 1-50ml were weak positive in 5 patients and intermediate 
positive in 4 patients. NPC with primary tumor volume 51-100ml were 
negative in 2 patients, weak positive in 1 patient, intermediate positive in 3 
patients, and strong positive in 2 patients. NPC with primary tumor volume 
>100ml were weak positive in 1 patient and strong positive in 1 patient. 
Statistic analysis result showed there is a correlation between EGFR 
expression and primary tumor volume (p<0.05) with coefisien correlation 
(r)=0.461, there was an intermediate positive relation between EGFR 
expression and primary tumor volume. 
The result is in accordance with the hypothesis, based on the theory that 
the NPC malignancy process indentify in EGFR signalling pathway. Braut 
et al., conducted study in 145 samples of biopsy tissue of head and neck 
squamous cell carcinoma using immunohistochemistry examination and 
found EGFR expression in control group were negative, hyperplastic group 
were weak positive, and carcinoma tissue were strong positive. The most 
significant changes was the supra basal layer [16]. Wang et al., found 
positive EGFR in 39 patients (70.9%) from 55 NPC cases that underwent 
immunohistochemistry examination, meanwhile negative EGFR in 29.1% 
cases. Chua et al., found the positive EGFR expression using 
immunohistochemistry examination in biopsy results were 89%, 
meandwhile negative EGFR  were 11%. The conclusion of the study there 
was no difference between EGFR expression with NPC staging, tumor size, 
lymph node enlargement, distant metastasis, age and gender. Sheen et al., 
found the positive EGFR 73.3% in all histology subtypes of NPC, consist of 
keratinizing squamous cell carcinoma in 6 cases, nonkeratinizing 
differentiated squamous cell carcinoma in 8 cases and nonkeratinizing 
undifferentiated in 27 cases [5].  
EGFR gives intracellular transduction signalling pathway  such as 
RAS/MAPK. The bond between growth factors and receptors are the initiation 
organization dan cell biochemistry process. The process are receptor 
activation, phosporilase cascade with indentification protein kinase and in 
nucleus level there is a transcription factors activation. EGFR system 
interaction and RAS/MAPK cascade is one of main cell pathways. Biological 
response to EGFR signal is pleiotrophic, including mitogenesis, inhibition 
apoptosis, induction cell motility, protein secretion and differentiation [17]. 
The effect of EGFR activation in tumor cell has many variations and 
also convergents that caused the uncontrollable cell growth, increased 
mobility, cell proliferation, invasion, metastasis, decreased of apoptosis and 
also stimulated the angiogenesis. In normal level of EGFR expressed by 
epithelial and mesenchymal cells. There were found increasing of EGFR 
expression in malignancy. Most of epithelial cancers expressed EGFR (over 
expression). EGFR over expression happens not only in NPC but also in 
others malignancies such as, colon carcinoma, glioma, ovarial carcinoma, 
kidney carcinoma, and lung carcinoma. The tumor cells with EGFR 
expression tent to be more aggressive and invasif [17]. 
The density of EGFR vary from nothing in the lymphoid cell until 
250.000/keratin cell. Head and neck squamous cell carcinoma tend to twice 







bigger compare to normal cell to cond with monoclonal EGFR antibody, 
therefore the EGFR expression is the indicator of malignancy 
transformation and related with tumor differentiation. High level of EGFR 
expression showed in undifferentiated carcinoma and in case of poor 
prognosis carcinoma. Excess EGFR expression used as a predictor of tumor 
agresiveness, eventhough in head and neck squamous cell carcinoma the 
worse prognosis usually because of the uncontrolled distant metastasis. 
EGFR involved in carcinoma pathogenesis in head and neck and cause the 
disease progressivity [4, 16]. 
EGFR increased in many carcinomas, it is a transmembranne 
glycoprotein that produced by c-erb-B2 proto oncogen. This protein 
expressed only few in human body, but the proto oncogen activations caused 
many kind of carcinomas in human body. In physiology state, epithelias cell 
improperly proliferated due to response mitogenic ligan EGF that secreted 
autokrin or parakrin, or presented thru intercellular signalling that could 
activated the EGFR. The cell triggered to proliferated thru EGF during 
healing. Those signals started by one of 11 EGF members. The whole EGF 
ligands members included in proform as a precursore transmembranne 
proteins. The ligands converted become activated form that can diffused 
thru extracellular protein membrane breakdown [18]. 
The excessive EGFR expressions usually found in squamous cell 
carcinomas, either in tumor tissue or cell culture. EGFR expression barely 
found in normal squamous epithelial without cancer in control group, and 
increased when EGFR related with dysplasia and tumor. In normal 
squamous epithelial, EGFR laid in basal cell and indicated that the signals 
that conducted by EGFR were needed for proliferation. Many studies that 
showed EGFR in basal cell normal epithelial tissues, indicated there is a 
certain transformation mechanism that increase the EGFR expression dan 
cause the uncontrollable tumor proliferation. There is a hypothesis stated 
disregulation of EGFR happens in two steps, the first step is excessive 
EGFR expression in normal epithelial tissue that close to tumor. The second 
step is the changing from dysplasia becomes squamous cell carcinoma 
because of the excessive EGFR expression [4]. 
In normal condition, EGFR expression range from 40.000 until 
100.000 receptors/cell. There is an increasing of EGFR expression about 
80-90% in head and neck squamous cell carcinoma. The increasing found 
in the early phase of carcinogenesis and increase gradually when tumor 
size gets bigger, it can be marker to observe histology abnormality start 
from displaia until in situ carcinoma [19].  
The mechanism of increasing EGFR in head and neck SCC in the early 
stage activated by conformational changes inducted by ligans (EGF, 
amphiregulin, and transforming factor alpha- TGFα). Those changes caused 
dymerization of receptors that stimulate intrinsic tirosine kinase proteins 
activation, phosphoriyation and receptors activation. The receptors 
activation inducted a signal transduction, includes Ras/Raf/mitogen-
activated protein kinas (MAPK), phosphoinositide 3-kinase (PI3K)-Akt, 
and transcription pathway activator. The MAPK that already 
phosphorylized will burn into nucleus, and making phosphorylation as a 
transcription factor that activated specific targeted gene expression, induce 
angiogenesis, proliferation, metastasis, invasion, and apoptosis inhibition 
[4]. 
Various studies show increasing EGFR expression predict poor 
prognosis and metastasis risk bigger in malignancy cases. EGFR expression 
reported as a prognosis factor in epithelial form of malignancy. The 
increasing EGFR expression usually uses to indentify big tumor size or 
related with distant metastasis [5]. 
The staging classification system using TNM that developed by 
YIML for NPC. T classification determined based on local anatomical 
location and cranial nerves that involved without quantitative criteria of 
tumor volume. Until now many studies have been conducted to link the 
tumor volume and controlled disease. NPC is the tumor that very 
infiltrative and tend to spread to soft tissue surround and skull base. 
Tumor volume can not be clinically measure easily without any modalities 
such as CT scan and MRI. The accurate assessment for tumor volume 
need tumor shape with several serials 3D imaging. There was many 
variations found of tumor volume from the same T classifications [20].  
T-classification usually associated with local control and worse 
condition, therefore patients with different tumor volume eventhough with 
the same T-classification could give different prognostic [20]. 
Volume or tumor size have been known as two from many prognostic 
factors in malignancy therapy. The main purpose of staging in malignancy 
is to divide the patients into groups based on prognosis and to determine the 
right therapy. Big tumor size used as an assessment for staging by measuring 
the tumor size and its spreading. For the case with resectable tumor, tumor 
size becomes less important in local control. In the other hand for the 
unresectable case, tumor size becomes more important in local control 
because the increase ricks of clonogen and big size tumor tend to consist of 
hipoxic area that can leads to resistency in radiotherapy [20]. 
Chu et al., did retrospective study in 100 new cases of NPC from 2002-
2006. The study used MRI for measure the primary tumor volume. This 
study showed primary tumor volume as a independent prognostic factor for 
distant metastasis, recurrency and quality of life after treatment [21]. 
Meanwhile according to Chua et al., primary tumor volume could not 
be use as a prognostic factor in early stage of NPC. Tumor volume >15ml 
had the worse local control but from 5 years survival rate there is no 
significant difference [21]. 
The number of samples were 19 patients, sample collected from 
September untul December 2017. The sampe collection is done with 
randomized sampling method using inclusion and exclusion criterias.                  
The study result there was intermediate positive correlation between EGFR 
expression and primary tumor volume (p<0.05). 
Therapy response could be assessed based on primary tumor volume 
(staging) but in fact NPC patients with the same primary tumor volume 
could showed different response, therefore we still need another additional 
examination to predict the therapy response. The good understanding in 
correlation between EGFR expression and primaty tumor volume could be 
use to predict the therapy response using anti EGFR drugs. 
 
5. CONCLUSION 
Nasopharyngeal carcinoma (NPC) is a malignancy derived from 
nasopharyngeal epithelial cells. One of the molecular NPC markers is 
cluster of Epidermal Growth Factor Receptor (EGFR) who have responsible 
against the proliferation, differensiation, apoptosis, metastasis and drug 
resistance. This study aims to prove the association expression of EGFR 
with primary tumor volume in patients with NPC. The conclusion in this 
study explains that there was association between expression of EGFR with 
primary tumor volume in-patients with NPC. 
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